Navigation Links
Onconase in Medical News

Alfacell Announces Management Update

... rolling New Drug Application (NDA) submission for onconase in patients suffering from unresectable malignant ...eeting at the end of January 2009. About onconase (R) onconase is a first-in-class therapeutic product candidate ...

Alfacell Reports Financial Results for First Quarter of Fiscal 2009

...leted a confirmatory Phase IIIb clinical trial for onconase in patients suffering from unresectable malignant ...etails of the planned NDA submission. About onconase (R) onconase is a first-in-class therapeutic product candidate ...

Alfacell to Host Fiscal First Quarter 2008 Financial Results Conference Call and Webcast

...nd other life-threatening diseases. In addition to an ongoing Phase IIIb study in malignant mesothelioma, Alfacell is conducting a Phase I/II trial of onconase in non-small cell lung cancer (NSCLC) and other solid tumors. For more information, visit http://www.alfacell.com . Safe Harbor This press releas...
Onconase in Medical Technology

Alfacell's Onconase Highlighted in Latest Edition of Handbook of Therapeutic Antibodies

BLOOMFIELD, N.J., March 20, 2007 /PRNewswire-FirstCall/ -- Alfacell Corporation's ONCONASE (ranpirnase) has shown potential to act as a potent payload in antibody conjugates for cancer therapy, according to the latest edition of the Handbook of Therapeutic Antibodies. In a chapter of the text th...

Preclinical Data Show Alfacell's Onconase Inhibits Tumor Growth of Non-Small Cell Lung Cancer, Breast Cancer Cells

Poster Presented at AACR Annual Meeting BLOOMFIELD, N.J., April 16, 2007 /PRNewswire-FirstCall/ -- Alfacell Corporation today announced that in vivo and in vitro preclinical data presented in a poster at the American Association for Cancer Research (AACR) Annual Meeting show that ONCONASE (ranpirn...

Studies Show Mild Hyperthermia Enhances Antitumor Effects of Alfacell's Onconase

BLOOMFIELD, N.J., March 22, 2007 /PRNewswire-FirstCall/ -- Alfacell Corporation today reported that in vitro studies show mild hyperthermia enhances the therapeutic effects of ONCONASE (ranpirnase), the company's lead investigational drug candidate. In a paper entitled, "Mild hyperthermia predis...

Researchers Identify Intracellular Pathway of Alfacell's Onconase

Paper Published in Journal of Cell Science Shows ONCONASE Uptake in Cells Differs from other RNases BLOOMFIELD, N.J., April 05, 2007 /PRNewswire-FirstCall/ -- Alfacell Corporation today announced that European researchers have identified the pathway that ONCONASE (ranpirnase) follows to enter cell...

Alfacell Provides Shareholder Update

...ofile, its ability to overcome MDR, I believe that onconase remains a viable candidate for second line therapy in MM. The fact that onconase was able to extend the lives of patients who had f...tudies on immune deficient mice to see what effect onconase would have on human tumors grafted onto these mice...

Alfacell Provides ONCONASE(R) NDA Submission Update

... planned submission of the final components of the onconase rolling New Drug Application (NDA) for the treatme... planned submission of the final components of the onconase rolling NDA for patients that have failed prior ch...y. Therefore, the final components of the rolling onconase NDA will not be finalized until Alfacell receives ...

Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacell's ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines

...py. The study demonstrated that the combination of onconase and rosiglitazone synergistically decreased cell v... The study concludes the novel drug combination of onconase and rosiglitazone is a promising combination. "T... in vivo studies and demonstrates the potential of onconase for effective use in cancer treatments via multipl...

Alfacell Announces ONCONASE(R) Distribution and Marketing Agreement with Megapharm for Israel

...product in our oncology portfolio. We believe that onconase will prove to be a promising new treatment option ...with an ideal partner to maximize the potential of onconase in this region. We look forward to a successful co...llaboration with Megapharm." About ONCONASE(R) onconase is a first-in-class therapeutic product candidate ...

Strativa Pharmaceuticals Announces Preliminary Results from ONCONASE(R) Phase IIIb Clinical Trial

...ry Phase IIIb clinical trial of its lead compound, onconase (ranpirnase), did not meet statistical significanc...MM patients who were treated with a combination of onconase plus doxorubicin as compared to patients who were ...val time (MST) for evaluable patients who received onconase plus doxorubicin was 11.1 months as compared to 10...

Alfacell Corporation Announces Preliminary Results From ONCONASE(R) Phase IIIb Clinical Trial

...MM patients who were treated with a combination of onconase plus doxorubicin as compared to patients who were ...val time (MST) for evaluable patients who received onconase plus doxorubicin was 11.1 months as compared to 10...ntering this clinical trial. Patients who received onconase plus doxorubicin experienced a MST of 10.5 months ...

More>>

Onconase in Biological Technology

Alfacell Provides ONCONASE(R) NDA Submission Update

... planned submission of the final components of the onconase rolling New Drug Application (NDA) for the treatme...rom the confirmatory Phase IIIb clinical trial for onconase in patients suffering from UMM did not meet statis...ation effective as of January 1, 2009. About onconase (R) ...

Alfacell's ONCONASE(R) and R-Amphinase Show Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Acute Myeloblastic Leukemia Cells

...ct 4205 & 2008 112: Abstract 4010) report that onconase (ranpirnase) and R-Amphinase (R-Amph) show anti-tu...tment of Pathology at New York Medical College . onconase and R-Amph are amphibian endoribonucleases with un...ammed cell death) of malignant cells. Previously, onconase has been shown to affect multiple cellular pathway...

Alfacell Reports Fiscal Fourth Quarter and Full Year 2008 Financial Results

...nt in a confirmatory Phase IIIb clinical trial for onconase in patients suffering from unresectable malignant ...ses required to complete the final sections of the onconase rolling NDA. As the company has previously reporte...nd completion of the Phase IIIb clinical trial for onconase in UMM. In fiscal 2009, we plan to complete the ND...

Paper in Cell Cycle Reports Alfacell's ONCONASE(R) Targets siRNA

...n Cell Cycle (2008; Vol. 7, Issue 20) reports that onconase (ranpirnase) targets small interfering RNA (siRNA)...he expression was restored in the cells exposed to onconase for 48 or 72 hours. The data thus provide evidence...his data provide further evidence of the impact of onconase on the RNAi mechanism," said Kuslima Shogen, Alfac...

Alfacell Hires Advisors to Advance Strategic Alternatives

...oved a specific transaction. About ONCONASE(R) onconase is a first-in-class therapeutic product candidate ... A natural protein isolated from the leopard frog, onconase has been shown in the laboratory and clinic to tar...facell has licensed the U.S. commercial rights for onconase to Strativa Pharmaceuticals, a division of Par Pha...

Alfacell Receives NASDAQ Delisting Letter

...e development of a new class of targeted therapies for cancer and other life-threatening diseases. Alfacell has completed Phase III clinical trials of onconase in unresectable malignant mesothelioma and, in addition to ongoing efforts to complete the related rolling New Drug Application, Alfacell is currently...

Alfacell Receives NASDAQ Non-Compliance Notification

...e development of a new class of targeted therapies for cancer and other life-threatening diseases. Alfacell has completed Phase III clinical trials of onconase in unresectable malignant mesothelioma and, in addition to ongoing efforts to complete the related rolling New Drug Application, Alfacell is currently...

Alfacell Reports Financial Results for Third Quarter of Fiscal 2008

...ent expectations for the planned completion of the onconase rolling NDA. The company will be eligible to recei...nt in a confirmatory Phase IIIb clinical trial for onconase in patients suffering from unresectable malignant ...ses required to complete the final sections of the onconase rolling NDA. As the company has previously reporte...

Alfacell Announces Retirement of Chief Executive Officer

...us upon receiving marketing approval by the FDA of onconase for the treatment of malignant mesothelioma, a sig...lfacell in the event aggregate annual net sales of onconase exceed $100 million. "Tina's contributions to Alfacell and the science behind onconase have been immeasurable," said David Sidransky, M.D...

Alfacell Reports Financial Results for Second Quarter of Fiscal 2008

... in the confirmatory Phase IIIb clinical trial for onconase (ranpirnase) in patients suffering from unresectab...rmaceutical, Inc. for the commercialization of onconase in the U.S. by Strativa, the branded product d...th BL&H Co. Ltd., for the commercialization of onconase in Korea, Taiwan and Hong Kong. Under the agr...
Other Tags
(Date:9/1/2015)... ... September 01, 2015 , ... PetPace, the provider of ... signs and activity, today announced its integration with leading veterinary Practice Management Software ... veterinary hospital Practice Management Software packages in the US. Practice Management Software helps ...
(Date:9/1/2015)... ... 2015 , ... Royal River Natural Foods, a locally-owned independent natural health store ... 19 years and found that, among those who had a stroke, people who used ... part of the September 2015 issue of “Natural Insights for Well Being,” which Royal ...
(Date:9/1/2015)... ... ... Two of Washington D.C.’s most respected chefs are using their global expertise ... named “the next big thing” in the culinary world by Elle Spain, award-winning culinary ... food and reclaiming culinary traditions on the brink of extinction. According to Amy and ...
(Date:9/1/2015)... ... September 01, 2015 , ... METTLER TOLEDO is pleased to ... the Connectivity Kit, EasySampler data is automatically transferred to, and reported with, the ... touchscreen platform. , EasySampler fully automates the sampling process including sampling ...
(Date:9/1/2015)... ... ... Ogawa’s new massage chairs tout innovative functionality that change the way robotic ... With the goal of bringing wellness to the world, Ogawa introduces their new line ... in its name, the Ogawa Refresh aims to “refresh” and rejuvenate the ...
Breaking Medicine News(10 mins):Health News:Petpace-Cornerstone Integration Lowers Overhead, Raises Data Visibility for Veterinary Practices 2Health News:New Study Finds Multivitamins Extend Life After Stroke, Retailer Reports 2Health News:Chefs Amy Riolo and Luigi Diotaiuti Embark on Culinary Diplomatic Quest to Build Bridges through Global Cuisine 2Health News:Chefs Amy Riolo and Luigi Diotaiuti Embark on Culinary Diplomatic Quest to Build Bridges through Global Cuisine 3Health News:Chefs Amy Riolo and Luigi Diotaiuti Embark on Culinary Diplomatic Quest to Build Bridges through Global Cuisine 4Health News:New Technology Allows Unattended Sampling and Synthesis of Chemical Reactions 2Health News:New Technology Allows Unattended Sampling and Synthesis of Chemical Reactions 3Health News:Ogawa World USA Releases New Massage Chairs to the US 2Health News:Ogawa World USA Releases New Massage Chairs to the US 3
(Date:8/5/2015)... 2015 Transparency Market Research has ... - Global Industry Analysis, Size, Share, Growth, Trends and ... recognition is forecast to reach US$ 2,671.8 Mn by ... surveillance systems by civil and government agencies. This is ... terrorist activities across the globe that would elevate the ...
(Date:8/3/2015)... 3, 2015 Synaptics, Inc. (Nasdaq: SYNA ... announced that members of the executive management team will ... Global Technology Leadership Forum on Tuesday, August 11, 2015 ... held at the Sonnenalp Resort in Vail, ... include forward-looking information. An audio webcast of the event ...
(Date:7/31/2015)... SHENZHEN , Chine, 31 juillet 2015 /PRNewswire/ ... (ICG-10, www.icg-10.org ) sera organisée par le ... Shenzhen en Chine. ... année. Depuis son inauguration en 2006, l,ICG est ... influentes dans le domaine des « omiques » et c,est ...
Breaking Biology News(10 mins):Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 4Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 5Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 6La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3
Other Contents